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Background: The optimal management of the pylorus during esophagogastrectomy is unknown. Pyloromyotomy
and pyloroplasty cause early edema and risk long-term bile reflux; however, the lack of pyloric drainage might
risk early aspiration.
Methods: We performed a retrospective study with a prospective database on patients with esophageal cancer or
high-grade dysplasia who underwent Ivor–Lewis esophagogastrectomy. All had one surgeon and similar stomach
tubularization, hand-sewn anastomoses, nasogastric tube duration, and postoperative prokinetic agents. Out-
comes of postoperative gastric emptying, aspiration, and swallowing symptoms were compared.
Results: Between January 1997 and June 2008, there were 221 patients. Seventy-one patients had a pyloromyot-
omy, and gastric emptying judged on postoperative day 4 was delayed in 93% (52% had any morbidity and 14%
had respiratory morbidity). Fifty-four patients had no drainage procedure, and gastric emptying was delayed in
96% (59% had any morbidity and 22% had respiratory morbidity). Twenty-eight patients underwent pyloro-
plasty, and 96% had delayed gastric emptying (50% had any morbidity and 32% had respiratory morbidity).
Sixty-eight patients had botulinum toxin injection into the pylorus. Gastric emptying was delayed in only
59% (P ¼ .002, 44% had any morbidity and 13% had respiratory morbidity). Hospital length of stay (P ¼
.015) and operative times (P ¼ .037) were shorter in the botulinum toxin group. Follow-up (mean, 40 months)
showed symptoms of biliary reflux to be lowest in the botulinum toxin group (P ¼ .024).
Conclusion: Injection of the pylorus with botulinum toxin at the time of esophagogastrectomy is safe and de-
creases operative time when compared with pyloroplasty or pyloromyotomy. In addition, it can improve early
gastric emptying, decrease respiratory complications, shorten hospital stay, and reduce late bile reflux. A prospec-
tive multi-institutional randomized trial is needed.
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SAlthough esophagectomy for cancer is a well-established op-
eration, there exists much controversy as to the optimal surgi-
cal approach and management of the pylorus. Many who
prefer pyloroplasty argue that it helps gastric emptying associ-
ated with pyloric denervated and hence reduces the risk of
pulmonary aspiration.1,2 However, it renders the pylorus
incompetent and risks life-long bile reflux after esophagogas-
trectomy. In contrast, it has been argued that other techniques,
such as pyloromyotomy or even no-pyloric-drainage proce-
dures, are preferred. We have practiced all 3 techniques and
have found that none are ideal. Although a pyloromyotomy
and pyloroplasty help the vagectomized and denervated stom-
ach empty, there is often edema after this procedure, and this
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doi:10.1016/j.jtcvs.2008.08.049The Journal of Thoracic and Coften prolongs gastric emptying in the early postoperative pe-
riod when the patient is at the highest risk of aspiration. In ad-
dition, it can lead to long-term bile reflux, for which there is no
satisfactory treatment. Conversely, if the pylorus is left alone
so as to avoid long-termbile reflux, the stomach often does not
empty well initially, and hence the risk of aspiration remains
increased. Aspiration and aspiration pneumonia are the most
common and devastating early postoperative complications
after esophagogastrectomy3,4 and have remained a vexing
problem in our practice. For these reasons, we postulated
that the intraoperative injection of Botulinum A 100 U toxin
(Allergan Pharmaceuticals, Westport, Ireland), or what is
more commonly calledBotox, at the time of esophagogastrec-
tomy might represent a promising solution to this controver-
sial but clinically important dilemma. Botox can promote
gastric empting for a few months after surgical intervention,
thereby reducing the risk of aspiration when it is most likely
and most lethal, but it should not cause long-term bile reflux
because its effects dissipate within a few months. We evalu-
ated our preliminary experience using Botox injection into
the pylorus at the time of esophagogastrectomy.
MATERIALS AND METHODS
This is a retrospective cohort study of a prospective database of a con-
secutive series of patients with distal or midesophageal cancer or those
with high-grade dysplasia who underwent Ivor–Lewis esophagogastrec-
tomy performed by one surgeon in an academic setting (the Universityardiovascular Surgery c Volume 137, Number 3 565
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Sof Alabama at Birmingham, Birmingham, Ala). All patients had their
stomachs tubularized in the same fashion. The fundus of the stomach,
the gastroesophageal junction, and the proximal portion of the lesser curve
were all removed with a stapling device. This staple line was then over-
sewn. The conduit’s width was approximately 6 cm in all patients, and
the anastomosis was constructed through an end of the esophagus to the
side of the stomach. The conduit was constructed so as not to be redundant,
to sit straight in the posterior mediastinal bed, and to have approximately 3
cm of stomach above the anastomosis. A standard Ivor–Lewis esophago-
gastrectomy was performed,5 and a hand-sewn anastomosis of the end
of the esophagus to the side of the stomach above the azygous vein was
constructed in all patients. Patients younger than 19 years of age or those
who underwent esophagogastrectomy for reasons other than dysplasia or
malignancy were excluded. In addition, patients who underwent a transhia-
tal or 3-hole6 esophagogastrectomy or a total esophagectomy with gastric
pull-up with a gastric–pharyngeal anastomosis were also excluded from
this study to decrease the effect that the location of the anastomosis or
remaining amount of native esophagus might have on emptying. Early
outcomes assessed and compared were operative times, morbidity rates,
operative mortality, gastric emptying, incidence of anastomotic leak, and
hospital length of stay. Late outcomes included the incidence of bile reflux
symptoms, as assessed by survey, and stricture rates, as assessed based on
the need for anastomotic dilation. Clinically significant bile reflux was as-
sessed at the time of the 3-week postoperative clinic visit; at 3, 6, and 9
months; and yearly thereafter by telephone. The specific questions used
to identify bile reflux were the patient’s reporting of nausea, vomiting after
or while eating, and/or the sensation of bland liquid regurgitating cranially,
pillow staining of dark material during sleep, or both.
For the purposes of this study, aspiration was defined as a patient with
altered eating habits or choking and/or coughing symptoms while swallow-
ing, clinical assessment consistent with aspiration in which medical inter-
vention was indicated (eg, urgent intubation, followed by bronchoscopy,
antibiotics, oxygen, and suction), or both. Pneumonia was defined as radio-
graphic findings of an infiltrate with an increased white blood cell count and
a fever along with clinical manifestation of respiratory distress (dyspnea,
hypoxia, and infection documented clinically or microbiologically) with
no evidence of an aspiratory event.7 Operative mortality includes any pa-
tient who died during his or her hospital stay or for any reason 30 days after
discharge. Weight change was defined as body weight at the time of the 3-
week postoperative follow-up visit subtracted from weight at the time of
hospital discharge.
Upper Gastrointestinal Swallow on Postoperative
Day 4
Gastric emptying was assessed by using an upper gastrointestinal swal-
low performed on postoperative day 4. The study started with the patient
drinking 50 to 75 mL of a water-soluble contrast agent. This was followed
by the drinking of 30 to 60 mL of barium contrast agent. In addition to the
use of fluoroscopy to assess swallowing, digital spot images were obtained
in multiple obliquities in both the upright and supine positions. A single gas-
trointestinal radiologist who was blinded to the type of pyloric procedure
performed retrospectively reviewed all of the studies and classified them
in one of 5 categories. The first category was labeled as ‘‘no delay’’ and
was defined as complete emptying of all contrast administered into the prox-
imal duodenum within 2 minutes. The second category, labeled ‘‘slight de-
lay,’’ was defined as emptying of all contrast material within 5 minutes. The
third category, labeled ‘‘mild delay,’’ was defined by complete emptying of
the oral contrast into the duodenum at 10 minutes. The fourth category, la-
beled ‘‘moderate delay,’’ was defined as the emptying of 50% or more of
the contrast at 10 minutes. The fifth and final category, labeled ‘‘significant
delay,’’ was defined as less than 50% emptying of the contrast after 10 min-
utes. These latter patients had a nasogastric tube temporarily reinserted, and
the contrast agent was removed. For statistical purposes, we then grouped
patients as having one of 3 levels of gastric emptying, as shown in566 The Journal of Thoracic and Cardiovascular SurTable 1. Level 1 indicated no delay and included only patients with category
1 emptying. Level 2 included patients with category 2 or 3 emptying, and
level 3 included patients with category 4 or 5 emptying. This study and
the prospective database were both approved by the University of Alabama
at Birmingham’s Institutional Review Board. Patient contest was obtained
for entry into the prospective database but was waived for this study.
Statistical Analysis
Data were analyzed by using the Student t test andWilcoxon and c2 tests,
as appropriate. A stepwise multivariate logistic regression model was used
to correct for the effect of multiple variables and their interactions for delay
of gastric emptying. Variables that were associated with gastric emptying
delay with a P value of less than .1 in the univariate analysis were entered
into the multivariate model. Software used was SAS version 9.1 (SAS Insti-
tute, Inc, Cary, NC).
Operative Technique
Ivor–Lewis esophagogastrectomy was accomplished through a 2-stage
operation, starting with a midline exploratory laparotomy incision with mo-
bilization of the stomach based on the right gastroepiploic artery. The sec-
ond phase consisted of a right posterior lateral thoracotomy, as previously
described.4,5 The pylorus was treated in 4 different ways during the abdom-
inal portion of the operation in this study. Each patient received only 1
therapy. Patients either had their pylorus left alone (also referred to as un-
dergoing no drainage procedure); underwent a pyloromyotomy or pyloro-
plasty, as previously described8; or had botulinum toxin (Botox) injection
of the pylorus. The latter procedure, not previously described intraopera-
tively, was accomplished by diluting 0.4 mL of Botulinum A 100 U toxin
(Allergan Pharmaceuticals) with 4 mL of normal saline. One milliliter of
the mixture was then injected into the muscle of all 4 quadrants of the py-
lorus during the operation by using a 22-gauge needle. This was done by
the operating surgeon and was not performed endoscopically.
Botulinum Toxin
In striated muscle botulinum toxin inhibits acetylcholine from choliner-
gic nerves. Botulinum toxin A selectively cleaves the synaptosomal-associ-
ated protein 25, leading to the inability of synaptic vesicles containing
neurotransmitters to undergo exocytosis and release neurotransmitters.9 In
gastrointestinal smooth muscle botulinum toxin appears to also reduce cho-
linergic transmission by inhibiting acetylcholine release, as shown in
in vitro10 and in vivo11 studies. Synaptosomal-associated protein 25 is
also present in gastrointestinal smooth muscle, suggesting an additional
site for botulinum toxin. Although the exact mechanism of botulinum toxin
in the smooth muscles is currently unknown, we do know that botulinum
toxin injection into the lower esophageal sphincter decreases lower esoph-
ageal sphincter tone and improves symptoms in achalasia.11 Botulinum
TABLE 1. Definitions of gastric emptying on postoperative day 4
swallow study
Category Descriptor Definition Level
1 None Prompt emptying, usually<2 min 1
2 Slight Majority of emptying (>90%) in 2–5 min 2
3 Mild Majority of emptying (>90%) in
6–10 min
4 Moderate Slow emptying over a period of 10
minutes, usually 25% to 90% emptied
in 10 min
3
5 Significant Little to no emptying, almost all contrast
remaining at 10 mingery c March 2009
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STABLE 2. Patient characteristics by pylorus treatment type
Pre-Botox group Botox group
Pyloroplasty Pyloromyotomy No drainage Botulinum toxin injection P value* Totals
No. of patients 28 71 54 68 NA 221
Sex (male) 20 (71%) 38 (53%) 37 (69%) 44 (65%) .823 139 (63%)
Dates performed January 1997–
December 2000
January 2001–
June 2005
July 2005–
October 2006
November 2006–
June 2008
NA January 1997–
June 2008
Median age (y [range]) 64 (23–74) 56 (43–76) 58 (25–88) 64 (41–74) .46 61 (23–88)
Histology NA
HGD 1 (4%) 5 (7%) 6 (11%) 5 (l7%) 17 (8%)
Adenocarcinoma 14 (50%) 36 (51%) 29 (54%) 39 (59%) 118 (53%)
Squamous cell 7 (25%) 16 (23%) 8 (15%) 11 (16%) 42 (19%)
NOS 6 (21%) 14 (20%) 11 (20%) 14 (18%) 44 (20%)
Neoadjuvant
chemoradiotherapy
13 (46%) 40 (56%) 23 (43%) 39 (57%) .362 115 (52%)
Pathologic stage .52
HGD/CR 8 (29%) 20 (28%) 18 (33%) 13 (16%) 59 (27%)
I 7 (25%) 26 (37%) 12 (22%) 28 (44%) 73 (33%)
II 6 (21%) 15 (21%) 20 (37%) 21 (32%) 62 (28%)
III 4 (14%) 7 (10%) 3 (6%) 6 (12%) 20 (9%)
IV 3 (11%) 3 (4%) 1 (2%) 0 (0%) 7 (3%)
HGD, High-grade dysplasia; NOS, not otherwise specified (usually in patients who were complete responders); CR, complete responder. *P value compares all pre-Botox groups
(pyloroplasty, pyloromyotomy, and no drainage) with the Botox group.toxin injection into the pyloric sphincter is reported to improve gastric emp-
tying and reduce dyspeptic symptoms in patients with gastroparesis.12,13 Its
pharmacologic duration is described to be approximately 90 to 120 days.
Postoperative Care
Patient care was administered as previously described.4 In summary, pa-
tients went directly to the floor from the operating room, and the intensive
care unit was not used as a routine. A nasogastric tube was placed at the time
of the operation and was removed on the morning of postoperative day 3.
Metoclopramide (Reglan, Baxter Pharmaceutical), erythromycin, and eso-
meprazol (Nexium, AstraZeneca Pharmaceuticals) were started on the day
of the operation. Swallows were done on postoperative day 4. Patients
were sent home on a 1-month course of erythromycin and a 3-month course
of esomeprazol.
RESULTS
There were 221 patients with a median age of 64 years
(range, 23–88 years) who underwent Ivor–Lewis esophago-
gastrectomy between January of 1997 and June of 2008 per-
formed by one surgeon. Over this time period, there were 32
patients who underwent either transhiatal total esophagogas-
trectomy with gastric to pharyngeal anastomosis or thora-
coabdominal or colonic interposition esophagogastrectomy
who were not included in this study. Patient characteristics
of the 221 patients are shown in Table 2 and stratified by
the type of pyloric management. There were no significant
differences in patient characteristics, comorbidities, and du-
ration of nasogastric tube use between the pre-Botox (no py-
loric manipulation, pyloroplasty, and pyloromyotomy) and
Botox groups. On univariate analysis, age greater than 70
years (P ¼ .043), neoadjuvant chemoradiotherapy (P ¼
.026), and the lack of Botox use (P ¼ .015) were predictorsThe Journal of Thoracic and Cof level 3 gastric emptying. On multivariable analysis, neo-
adjuvant therapy (P 0.031; odds ratio, 1.8; 95% confidence
interval, 1.09–2.41) and the lack of Botox use (P ¼ .016;
odds ratio, 2.9; 95% confidence interval, 1.68–3.86)
remained significant predictors of delayed gastric emptying.
Table 3 shows the delay and postoperative morbidity expe-
rienced by patients in each group. It shows that only 59% of
patients who received botulinum toxin experienced gastric
delay on the postoperative day 4 swallow study. A signifi-
cantly greater proportion of patients who underwent no
drainage procedure, pyloromyotomy, or pyloroplasty had
gastric delay compared with those who had Botox injected
into their pylorus (96%, 93%, 96%, and 59%, respectively;
P< .001). As shown in Table 3, hospital length of stay
(P ¼ .015) and operative time (P ¼ .037) were shorter in
the Botox group. Follow-up (mean, 40 months) showed
symptoms of biliary reflux to be lowest in the Botox group
(P ¼ .024). Patient weight decreased a median of 7.2 lbs
in the pre-Botox group and 4.9 lbs in the Botox group
(P ¼ .028). There was no relation between stricture rate
and symptoms of biliary reflux or aspiration.
DISCUSSION
The ideal treatment of the pylorus during esophagogas-
trectomy is unknown. Determination of the optimal manage-
ment is difficult because it is contingent on many protean
factors. Some of these variables are the indication for esoph-
agogastrectomy, the use of neoadjuvant chemoradiotherapy,
the type of esophagogastrectomy performed, the manner in
which the stomach is cut or stapled, the surgeon, the typeardiovascular Surgery c Volume 137, Number 3 567
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STABLE 3. Early and late postoperative outcomes
Pyloroplasty Pyloromyotomy No drainage Botulinum toxin
No. of patients (%) 28 71 54 68
Median duration of operation (h)* 4.3 3.9 3.5 3.3
Gastric delay on postoperative day 4 swallowy 96% 93% 96% 59%
Level 1 (no delay)y 1 (4%) 5 (7%) 2 (4%) 27 (41%)
Level 2 delay (‘‘slight’’ or ‘‘mild’’)y 13 (46%) 22 (32%) 15 (27%) 19 (28%)
Level 3 delay (‘‘moderate’’ or ‘‘severe’’)y 14 (50%) 42 (61%) 37 (69%) 21 (31%)
Morbidity 14 (50%) 32 (52%) 32 (59%) 30 (44%)
Pneumonia/aspiration 9 (32%) 10 (14%) 12 (22%) 9 (13%)
Mortality 1 (4%) 4 (6%) 2 (4%) 3 (4.4%)
Anastomotic leak 0 0 1 0
Hospital length of stay, median (d) 8.7 9.5 8.2 7.3
Symptoms of bile reflux 10 (38%) 14 (20%) 5 (9%) 4 (6%)
Stricture (requiring dilation) 4 (14%) 6 (8.4%) 4 (7.4%) 5 (7.3%)
*Includes turning of patient for thoracotomy. yDoes not total the number of patients in each group because of mortality before the postoperative day 4 swallow.and location of the anastomosis, the location at which the
conduit is positioned, the length of time the stomach is
drained, the operative time, the point at which gastric emp-
tying is studied, and the use of prokinetic agents. Although
this series is unique in that all of these factors were essen-
tially the same in each group over time, the study is non-
randomized, nuclear gastric emptying studies were not
used, and swallowing was only radiologically assessed at
one point in time. In addition, the patients who received bot-
ulinum toxin had all been operated on last when the surgeon
and his team were the most experienced. However, the swal-
lowing studies were done consistently in the same manner
and at the same time (on postoperative day 4) and read by
one radiologist who was blinded to the pyloric procedure.
Despite these flaws, the results are provocative.
There have been several prospective studies that have at-
tempted to answer the question of the ideal pyloric empty-
ing procedure during esophagogastrectomy, but they too
have all been either underpowered or flawed. In this study
we have shown that intraoperative injection of Botox into
the pylorus at the time of the resection shortens the opera-
tive time, is safe, and is easy to do. It might also help re-
duce gastric emptying delay and decrease bile reflux. A
true multi-institutional study is needed to fully answer
this important question, but its design must take into ac-
count some of the variables mentioned above, along with
others. Once multiple surgeons are asked to participate in
such a study, many other confounding variables are intro-
duced. Despite the lack of perfect data to fully answer the
controversial question of how to best handle the pylorus
at the time of esophagogastrectomy, several important con-
cepts are known.
Fok and colleagues,14 in 1991, published the largest
prospective randomized study on this issue. They random-
ized 200 patients: 100 received a pyloroplasty, and 100
received no drainage procedure. All patients had their
whole stomachs used, and they all underwent a Lewis–568 The Journal of Thoracic and Cardiovascular SuTanner operation.15 Fok and colleagues14 reported that
13 patients who received no drainage procedure had gas-
tric outlet obstruction, 1 required reoperation, and 4 expe-
rienced pulmonary complications, of which 2 died. This
study would suggest that pyloric drainage, specifically py-
loroplasty, is superior to no drainage for patients who un-
dergo esophagogastrectomy when the entire stomach is the
conduit selected. However, Mannell and associates,16 in
1990, showed in a prospective randomized trial that pylo-
roplasty led to dumping syndrome and bile reflux. Al-
though this report involved patients who had a gastric
conduit placed retrosternally, the notion that a pyloroplasty
might convert a unidirectional sphincter into a bidirectional
nonvalved conduit is not new. Furthermore, leakage from
a pyloromyotomy or pyloroplasty can occur, and this adds
another possible complication. Because the pylorus often
is located at the level of the diaphragm after esophagogas-
trectomy, a leak from a pyloromyotomy or pyloroplasty
can be located in the chest, the abdomen, or both and
can therefore be difficult to manage. In addition, Zieren
et al,17 in 1995, showed that patients who undergo pyloro-
plasty can have a late pyloric stricture as well. Thus these
procedures, although relatively safe, can lead to significant
complications.
Given these reports and because pyloromyotomy has
similar results (and sometimes a pyloromyotomy ends up
turning into a pyloroplasty), we began omitting any type
of pyloric drainage procedure during our Ivor–Lewis
esophagogasrectomies. A recent study from Low18 reported
a series of 301 patients who underwent esophagogastrec-
tomy, of which 287 had no drainage procedure. The inci-
dence of aspiration was exceedingly low in that study,
and the operative mortality was only 0.3%. These data
and presentation led us to change our technique. Starting
in July 2005, we began to eliminate the performance of
any drainage procedure. This thinking was supported by
others. Palmes and colleagues,19 in 2007, reported on 198rgery c March 2009
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Spatients and concluded that ‘‘pyloric drainage after esoph-
agectomy with gastric conduit reconstruction should be
omitted because it does not improve gastric emptying and
may favor biliary reflux esophagitis.’’ Similarly, Doning-
ton20 stated in 2006 that ‘‘the role of pyloric drainage
and the control of reflux is a double edged sword. It seems
to improve emptying but it also has the potential to increase
reflux of bile from the duodenum.’’ Thus we changed our
technique and performed 54 consecutive Ivor–Lewis oper-
ations and omitted any type of pyloric drainage procedures.
We left the pylorus alone. As shown in Table 2, we noted
poor gastric emptying on our postoperative day 4 swallows,
and 22% of patients had aspirations, pneumonias, or respi-
ratory complications. We also had 2 mortalities, and both
were due to aspiration. In our hands the technique of pylo-
rus sparing was not successful. Because we had referred
several of these patients who had poor gastric emptying
for endoscopic Botox injection after surgical intervention,
we then considered the idea of injecting Botox directly
into the pylorus at the time of the operation ourselves while
the abdomen was open. The concept was attractive to us be-
cause it theoretically might help promote gastric emptying
during the time the patient was most at risk of aspiration
(for a few months after the operation), and yet at the
same time, it might avoid the long-term side effects of per-
manent pyloric drainage and subsequent bile reflux for
which there is little effective therapy. Because we had no
previous reference to go by, we used the dose of 0.4 mL
of 100 U of botulinum toxin diluted in 4 mL of normal
saline with 4-quadrant injection because that was how our
endoscopic colleagues delivered it from the stomach–
duodenal junction. We used the same dose and 4-quadrant
injection, only we did it from the outside the pylorus into
the muscle at the time of the laparotomy.
In the past 68 Ivor–Lewis esophagogastrectomies, we
have performed intraoperative Botox injection, and the re-
sults have been good to excellent. Two of our gastrointesti-
nal radiologists immediately noticed the difference in many
(but not all) of our postoperative studies and inquired what
we were doing differently to achieve such a dramatically dif-
ferent radiologic result. The edema from a pyloroplasty or
pyloromyotomy was gone, and the poor gastric emptying
we observed in patients who received no drainage procedure
was also gone. Most importantly, the radiologic improve-
ments translated into improved clinical outcomes. As seen
in Table 2, the incidence of aspiration and pneumonias has
been reduced, and patients have enjoyed improved func-
tional swallowing results sooner and less bile reflux later.
However, the results are not perfect.
The limitations of this study include the small sample size
and lack of randomization. Moreover, the patients who re-
ceived Botox also had the most experienced surgical team
when compared with the other 3 groups of patients. The fol-
low-up is not as long in the Botox group as it is in the otherThe Journal of Thoracic and Cgroups, and it is possible that some patients might not have
yet had bile reflux. However, our follow-up seems long
enough in a large number of patients based on the time it
took the patients in the other groups to experience their
bile reflux to show a significantly reduced rate.
Another potential limitation was that we used a question-
naire to assess bile reflux instead of radiologic studies.
Although radiologic studies can be more sensitive, they are
expensive and of little use if results are positive in a patient
who is gaining weight and eating and swallowing well. The
strengths of this study are the minimization of confounders,
as described above, by using one surgeon and very similar
intraoperative and postoperative techniques. Other strengths
include the use of a prospective database, the construction of
the conduit and anastomosis in the samemanner and position,
the same nasogastric tube duration, the same type and duration
of prokinetic agents, the reading of all swallows by one radi-
ologist who reviewed each patient’s swallowing study, and
performance of swallows on the same postoperative day in
each patient. In addition, by eliminating other types of esoph-
agogastrectomies in this study, we eliminated the possible
effects that the location of the anastomosis or the amount of
native esophagus left in place could have on our results.
In conclusion, in this preliminary nonrandomized retro-
spective study on 221 patients, we have shown that the intra-
operative injection of botulinum toxin into the pylorus at the
time of esophagogastrectomy is safe and effective and de-
creases the operative time of the Ivor–Lewis operation. In
addition, we have provided provocative preliminary data
that it might also improve the immediate emptying of the va-
gectomized stomach and decrease the operative morbidity
by reducing the incidence of aspiration and pneumonia.
This technique might also reduce length of stay as well. Fur-
ther carefully designed prospective multi-intuitional studies
are needed to answer this important clinical question, and
this study might provide safety data for the framework for
such a study.
References
1. Cheung HC, Siu KF, Wong J. Is pyloroplasty necessary in esophageal replace-
ment by stomach? A prospective, randomized controlled trial. Surgery. 1987;
102:19-24.
2. Urschel JD, Blewett CJ, Young JE, Miller JD, Bennett WF. Pyloric drainage
(pyloroplasty) or no drainage in gastric reconstruction after esophagectomy:
a meta-analysis of randomized controlled trials. Digest Surg. 2002;19:160-4.
3. Atkins BZ, Shah AS, Hutcheson KA, et al. Reducing hospital morbidity and
mortality following esophagectomy. Ann Thorac Surg. 2004;78:1170-6.
4. Cerfolio RJ, Bryant AS, Bass CS, Alexander JR, Bartolucci AA. Fast tracking
after Ivor Lewis esophagogastrectomy. Chest. 2004;126:1187-94.
5. Patterson GA, Cooper JD, Deslauriers Lerat AE, Luketich JD, Rice TW. Esoph-
agetomy via right thoracotomy. vol 2. 3rd ed. Philadelphia, PA: Churchill Living-
stone; 2008. p. 590-6.
6. McKeown KC. Total three-stage oesophagectomy for cancer of the oesophagus.
Br J Surg. 1976;63:259-62.
7. National Institute of Health. Common terminology criteria for adverse events
(CTCAE) v. 3.0; 2003:56-8.
8. Soreide JA, Soreide K. Heineke-Mikulicz, Finney. Pylorplasty. In: Operative
techniques in general surgery. Vol. 5. p. 65-72.ardiovascular Surgery c Volume 137, Number 3 569
General Thoracic Surgery Cerfolio et al
G
T
S9. Blasi J, Chapman ER, Link E, et al. Botulinum toxin A selectively cleaves the syn-
aptic protein SNAP-25. Nature. 1993;365:160-3.
10. MacKenzie I, Burnstock G, Dolly JO. The effects of purified botulinum
neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-
resistant autonomic neuromuscular transmission. Neuroscience. 1982;7:
997-1006.
11. Pasricha PJ, RavichWJ, Hendrix TR, Kaloo AV. Intrasphincteric botulinum toxin
for the treatment of achalasia. N Engl J Med. 1995;332:774-8.
12. Ezzedine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of bot-
ulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc. 2002;
55:920-3.
13. Miller LS, Szych GA, Kantor SB, et al. Treatment of idiopathic gastroparesis with
injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroen-
terol. 2002;97:1653-60.
14. Fok M, Cheng SW, Wong J. Pyloroplasty versus no drainage in gastric replace-
ment of the esophagus. Am J Surg. 1991;162:447-52.
15. Ong GB, Kwong KH. The Lewis-Tanner operation for cancer of the oesophagus.
J R Coll Surg Edinb. 1969;14:3-19.
16. Mannell A, McKnight A, Esser JD. Role of pyloroplasty in the retrosternal stom-
ach: results of a prospective, randomized, controlled trial. Br J Surg. 1990;77:
57-9.
17. Zieren HU, Muller JM, Jacobi CA, Pichmaier L. Should a pyloroplasty be carried
out in stomach transposition after subtotal esophagectomy with esophago-gastric
anastomosis at the neck? A prospective randomized study. Chirurg. 1995;66:
319-32.
18. Low DE. Esophageal resection: improved outcomes associated with a diversified
approach. Abstract read at: 31st Annual Meeting of theWestern Thoracic Surgical
Association; June 22–25, 2008; Victoria, British Columbia, Canada.
19. Palmes D, Weilinghoff M, Colombo-Benkmann M, Senninger N, Bruewer M. Ef-
fect of pyloric drainage procedures on gastric passage and bile reflux after esoph-
agectomy with gastric conduit reconstruction. Langenbecks Arch Surg. 2007;392:
135-41.
20. Donington JS. Functional conduit disorders after esophagectomy. Thorac Surg
Clin. 2006;16:53-62.
Discussion
Dr Ross Bremner (Phoenix, Ariz). Thank you very much, and
congratulations on yet another great presentation and certainly
a very interesting and clearly written article.
The optimal drainage procedure for gastric interposition has
been debated perhaps even longer than the optimal treatment for
stage III lung cancer, but I will try to be brief. The idea of a quick
Botox injection is indeed intriguing, and although you do not mea-
sure the time it takes to do the Botox procedure versus a formal
pyloric procedure, I am sure your conclusion that it is quicker is
probably correct. I do have a couple of questions.
How exactly do you do this? How expensive is the drug, and do
you know intraoperatively that you have done it adequately? Can
you feel that the muscle is now paralyzed?
Dr Cerfolio. Thank you, and those are good questions. We do
not put a scope into the stomach and look endoscopically to ensure
proper placement, if that is what you mean. We do it by touch. The
pylorus is easily palpated. We inject Botox into it in all 4 quadrants,
and we are very careful on the side next to the gastroepiploic artery.
We inject the Botox in equal parts into all 4 quadrants. Because I
had really no baseline to go on, no previous publications on this
new idea to read, or anyone to ask, I just curb-sided my gastrointes-
tinal guys and decided to copy what they were doing endoscopi-
cally and do it open at the time of laparotomy. You can see the
Botox go into the pylorus; you get a little wheal when you are
injecting it sort of in the submucosal area, and then I just sort of
massage that in like a plastic surgeon does on the forehead. I
have talked to a couple plastic surgeons, and I guess that is what570 The Journal of Thoracic and Cardiovascular Surthey do when they do eyebrows and foreheads. Again, I just really
made this up.
Dr Bremner. How expensive is it?
Dr Cerfolio. It is expensive. Actually, it is interesting that the
billing office at the University of Alabama at Birmingham is very
aggressive with our operative notes, and they actually bill for it.
There is some code for chemodenervation of the muscle I see
when I get these operative notes to sign, and therefore one can
and should bill for it.
Dr Bremner. I am a little concerned about the temporary nature
of Botox. From the experience of gastroparesis and endoscopic Bo-
tox, we know that it lasts just about 3 to 5 months. In our cases in
which we have had to do a later operation to open up the pylorus for
gastric emptying, it is usually donemore than 6months later. I won-
der whether you have had any of your patients in whom you have
had to do an endoscopic redo Botox procedure if they had gastric
emptying problems?
Dr Cerfolio. We have not had to do that yet in the Botox group.
Now we certainly have used Botox in the other patients who have
very slow emptying, but I think that is much easier than a redo or
first-time pyloromyotomy after esophagectomy when the pylorus
is in no man’s land at the level of the diaphragm. I have never
gone back and had to reoperate on any of these patients for pyloric
obstruction, but we have used Botox in the other group, especially
in the group in which we did not do anything to the pylorus initially.
I think it works. But in those in whom we have treated the pylorus
initially with Botox, I have been thrilled with their emptying, even
after 3 to 5 months.
Dr Bremner. Do you have a very narrow conduit?
Dr Cerfolio. We tubularize the conduit to about 5 or 6 cm in
each patient. I think it is a real mistake to make the conduit too
wide or too redundant. I keep the stomach straight and narrow
and tall: a straight shot into the abdomen from the chest.
Dr Bremner. The study is unfortunately limited because you
stated here and well in the article that the objective data on long-
term emptying are not there, and I think it would be really nice if
you could do a radiographic emptying study, even on a subsection
of these patients. I mean, if you could just randomly select 20
patients from each of the groups and do an emptying study a year
or 2 down the line, it would be really nice to see what that it looks
like and perhaps even do a nuclear study to see whether there is any
bile reflux. Do you plan on doing something like that?
Dr Cerfolio. You are right, and we have some data on some of
the patients, but as I told Ayesha (and we all know Ayesha, she
was supposed to present this), unless you have the data for all
the patients, it does not make sense to show them for some pa-
tients. We really have data for only a few patients who were having
problems. I would argue that I am in this to take care of the patient.
If the patient is happy and swallowing well and maintaining his or
her weight, I do not care too much what it looks like on some
study, so why do it? I think our surveys, which were very accurate
and in which we used the same script on everybody, were our best
objective criteria of how they were swallowing. I think if we do
a prospective multi-institutional study on the best way to handle
the pylorus (ie, pyloromyotomy, nothing, or Botox), then we
will have to build the cost of that in. Also, it will be harder to
tell the patients that if they are doing well, they have to come
back and have a swallow test at 3 or 6 months, but that mightgery c March 2009
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Sbe the way to design it prospectively to really have data to answer
the question. I am biased now and would favor the Botox group
because I am convinced after doing all 3 procedures that it offers
the best results.
Dr Bremner. Finally, you noted that the chemoradiation group
had prolonged or delayed gastric emptying. Do you have a reason
for this?
Dr Cerfolio. Well, I do not know the exact reason. I can guess. I
am not sure, but I think it has to do with the fact that the conduit is
now being radiated. It clearly is in the radiated field and then on top
of a surgical manipulation, of grabbing it, stapling it, denervating it:
all those things together add up.
Dr Bremner. I think that possibly a narrow conduit or Botox
might be the answer, and I really look forward to participating in
a prospective trial like you mentioned. Thank you very much,
and thank you for the privilege of discussing the article.
Dr Cerfolio. Thank you.
Dr Richard Whyte (Stanford, Calif). Cerf, I enjoyed your arti-
cle. It was really very good. I have a quick question, though. You
had talked about using metoclopramide, erythromycin, and esome-
prazol in these patients. Did you use that same combination
throughout the years of the trial, or did that vary as well?
Dr Cerfolio. We were supposed to use it all the way through. If
you looked at some of the first patients, theymight not have gotten it
every day postoperatively, but everyone was supposed to receive it.
After that, though, our postoperative algorithmswerewell described
with high compliance, and thus the vastmajority of the patients have
been receiving them all. We do not use the metoclopramide out for
a month, but in the hospital we have been trying to do that. When I
was atMayo, I was lucky enough to spend timewithDrKeith Kelly,
who is a general surgeonwho spent a careerworking on gastric emp-
tying, and I spent 3monthswith him, so I alwayswas very interested
in gastric emptying, and we sort of stole some of his ideas for these
patients. It is not really in the thoracic literature, but Dr Jessica Don-
nington has written a nice chapter on the use of this treatment in the
thoracic surgical clinics.
Dr Donald Low (Seattle, Wash). First of all, as usual, this is
a very innovative, very interesting, and appropriate idea that we
should be looking at carefully regarding the management of these
patients. I notice that, first of all, you use the shotgun approach.
You start everything on everyone in every case before you do
your assessment.
Dr Cerfolio. Yes, just like I coach my Little League teams: we
come out running trying to steal bases early, and in basketball we
start off with a full-court press right out of the shoot. We come
out in the first inning and quarter and throw everything at them
to win the ballgame. Absolutely.
Dr Low. That is great. Maybe as far as winning that is good, but
maybe not for cost-effectiveness and assessing the results of overall
outcomes. First of all, you do not do a kocherization?
Dr Cerfolio. No.
Dr Low. For those of us who do this regularly, we recognize
sometimes the duodenum is very mobile. It is all ready. You can
move it right up to the esophageal hiatus. In other situations it is
very tacked down, and I think one of the issues regarding emptying
is making sure your conduit is verticalized and straight and that the
pylorus is sitting 2 to 3 cm below the hiatus in a straightforward
way. Do you not think that should be a part of the assessmentThe Journal of Thoracic and Cand the intraoperative aspects of what we are doing to ensure
good emptying at the time of surgical intervention?
Dr Cerfolio. It is a great question. It is one of the flaws of the
study course. One of the reasons I stopped doing a Kocher maneu-
ver is that I am not convinced that it makes a difference. But I totally
agree that the stomach should not be redundant or floppy because
over time it always gets worse. If you see those patients back at 3
or 4 years and if they are alive and they have a big floppy conduit,
they empty poorly. They look like they have long-standing achala-
sia with a sigmoid esophagus, and therefore I take out so much
stomach when I am in the chest, not as much in the neck, that I
asked myself why I was taking the time to do a Kocher maneuver
when I am resecting so much stomach. The conduit was still
straight and tall without the Kocher maneuver, it seemed. It took
time: not much, but some. There is some risk, but not much, but
everything is about efficiency and speed, and I think that the Kocher
maneuver did not make a difference. Now it is funny how some-
times you do not do a Kocher maneuver and yet sometimes you still
have a very nice straight column and sometimes you do not. If
someone has had a previous operation and they are socked in there,
I will take that down a little bit to try to ensure the conduit is ver-
tical, but I know that patients do not need a formal Kocher maneu-
ver to get a straight verticalized conduit.
Dr Low. One of the many things you are well known for is your
clinical pathways and fast tracking. I assume that includes the rein-
itiation of dietary profiles after surgical intervention.
Dr Cerfolio. Right.
Dr Low. What we have found is that some of the aspects of as-
piration, emptying, and so on have to do with what you are feeding
the patient, and a lot of the feedback we get has to do with that bar-
ium swallow that you do at 4 days. Do you think that we are too
far into clinical pathways and that we should be assessing these
swallows ourselves to assess how we should be introducing
erythromycin, metoclopramide, dietary profile, and Botox on an
individual basis rather than for baseball teams and for surgical
patients using.
Dr Cerfolio.. or basketball. That is another very good point. I
think that the team is the critical thing, and it is really not the sur-
geon. You guys know I am not modest, but it is the team, especially
with patients undergoing esophagectomy. I am, without a doubt,
the most easily replaced part of the team. We now have several
supernurses who just take care of the patients who have had esoph-
agectomies. We have a team of swallowing specialist nurses,
a speech and swallowing team that comes by and does these stud-
ies. We have radiologists who are very into doing this and making
sure—because we have had a death in the radiology suite after
a swallow—that it is being done correctly and safely. Therefore I
think your point is right. There are some patients in whom probably
you should not do a swallow test on the fourth or fifth day because it
is just not safe. They are not ready. They do not pass their bedside
swallow test, which we do on everyone first before we send them
for a swallow test. If they have poor emptying and a column of bar-
ium in their conduit, then the radiologist places a soft small catheter
through the anastomosis and sucks everything out to prevent aspi-
ration, but I think your point is well taken.
Dr Jemi Olak (Bakersfield, Calif). How did you measure bile
reflux in your patients in the postoperative period and then subse-
quently?ardiovascular Surgery c Volume 137, Number 3 571
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SDr Cerfolio. We did not measure it scientifically, as you sug-
gest, but we did measure it clinically. We have a survey that goes
all the way from what they eat and how they eat to looking at their
dumping symptoms. We ask things like whether they have any type
of sensation of things coming up. A lot of these people had endos-
copies afterward. Was there evidence of bile coming up? Pillow
staining was a specific question they were all asked to assess for572 The Journal of Thoracic and Cardiovascular Subile reflux as well. Therefore a very specific survey, I think, was
the best way I could get a handle on it, but you are right, it is not
scientific. It is not a radionucleotide tag particle that is bound to
the bile molecule to see whether it is coming up, which would be
nice but is really not practical or very cost-effective. Most impor-
tantly, if the patient is happy and asymptomatic, I am not sure
what I would do with that information.rgery c March 2009
